Scheduled Maintenance Notification
Website maintenance will begin Thursday March 20th, 12:00 pm – 3:00 pm PST. During this time, access to online ordering, order tracker, Software Downloads and MyTech Docs will not be available.
Please do not use these website features during this time. We will resume operations as soon as possible.
Products & Solutions
Back
Products & Solutions
Core Disciplines
Chemistry Immunoassay Hematology Urinalysis Microbiology Blood Banking Clinical Decision Support Protein Chemistry Service
Workflow & Informatics
Automation Systems DxA 5000 Total Lab Automation DxA 5000 Fit Automation System Advanced Informatics Remisol Advance Middleware Remote Services & Diagnostics
Solutions For
Antimicrobial Resistance Advantaged Workflows Pioneering Digital Hematology Neurology High Sensitivity Diagnostics Host Response to Infection Cardiovascular Disease IDBV Solutions Diabetes Diagnostics Drug Monitoring & Detection Sepsis
Support
Back
Support
Account Support
Create Account Manage Account Settings View All Account Support
Product Support
DxS Service In Vitro Diagnostic Regulation (IVDR) Manage My Technical Documents Search for Technical Documents Safety Data Sheets (SDS/MSDS) Search for Software Downloads Technical Documents Overview Manage My Regulatory Notifications Manage My Warranties & Agreements Request Instrument Support View Services Information View All Product Support Access Quality Assurance Programs
Ordering Support
Order Status & Tracking Track My Invoices View Return/RMA Policy Get Help with Orders View All Ordering Support
Resources
Back
Resources
Product Training
Browse Learning Lab › Learning Lab Login ›
Education & Research
Webinars Posters
Insights
Clinical Studies & Trends Case Studies Publications
Company
Back
Company
People & Culture
Overview Sustainability Meet Our Teams Diversity + Inclusion How We Work History and Innovation
Careers
Job Search › Programs & Grants Office Locations
News & Events
Awards & Recognition Newsroom Blog Events Calendar
Home / Clinical Laboratory Diagnostic Products and Solutions / Immunoassay / Neurology

Assays Education Request more

 

Rising to a Global Challenge

Fueled by epidemiological factors including population growth and longer life expectancies, cases of neurodegenerative diseases are expected to triple by 2050,1 placing financial and emotional burdens on patients, their caregivers, and healthcare systems. Current neurodegenerative disease diagnostics are limited by non-specific clinical symptoms, challenges in early diagnosis, and the high cost of available testing, creating an urgent need for affordable, scalable, and accessible blood-based diagnostics.


Leveraging our decades of IVD expertise, we’re creating best-in-class, highly sensitive, easy-to-use assays to ultimately improve testing accessibility and enhance clinical decision making to forever change how neurodegenerative diseases are investigated, diagnosed, and monitored

Leading the Way in Neurodegenerative
Research & Development

blood based biomarkers

Confidence in Your Results

Our high-quality assays enable researchers to detect and quantify blood-based biomarkers for neurodegenerative diseases with the exceptional sensitivity and specificity you’ve come to expect from Beckman Coulter.

And our partnerships with world-class research centers facilitate a deeper understanding of biomarkers involved in conditions such as Alzheimer's disease.

Blood-based Neurology Disease Assays

Assays for Research Use Only FU Information Bulletin
p-Tau217 Link Coming soon
GFAP Link Link
NfL Link Link
APOE ε4 Link Link
Research Use Only Assays in Development
ß-AmyIoid 1-42
BD Tau
MTBR-Tau
TDP-43
Assay has been granted BDD from the U.S. FDA
p-Tau217/ß-AmyIoid 1-42 Plasma Ratio*

*IVD Assay in Development. Not currently for use in diagnostic procedures.

 

Fully Automated APOE ε4 Testing

Our newly available APOE ε4 RUO blood-based immunoassay offers >99% concordance with PCR genotyping—in only 20 minutes. While not
diagnostic, APOE ε4 status can provide insights into risk of developing Alzheimer’s disease.

Read Study



 

 

“We are investing in our immunoassay technology to develop new, blood-based, high throughput, high sensitivity assays to detect and measure neurological biomarkers at a scale to address the growing global challenge."
Kevin O'Reilly
President, Beckman Coulter Diagnostics


Scalable Immunoassay Solutions to Match Your Lab 

Our RUO neurology assays run on the following Beckman Coulter Immunoassay Analyzers 

DxI 9000
Immunoassay Analyzer

Learn more

Access 2 
Immunoassay Analyzer 

Learn more

Building on our legacy of innovation, we are advancing the future of diagnostics around the globe to deliver accurate,
affordable testing solutions at scale.

High-throughput and highly sensitive. Our patented Lumi-Phos PRO substrate comes to full glow in under a minute.

Westgard analysis showed that the DxI 9000 analyzer had more assays achieving 6σ than any of our competitors

PrecisionVision technology directly monitors critical assay processing steps to identify errors and direct course correction in real time.

Educational Resources

Partnering to improve patient outcomes. Together, we can make a difference. Request more information.

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext"doi:10.1016/S2468-2667(21)00249-8

2. World Health Organization. Parkinson disease. August 9, 2023. Accessed February 7, 2025. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease

3. Guan B, Anderson DB, Chen L, Feng S, Zhou H. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. BMJ Open. 2023;13(10):e075049. https://bmjopen.bmj.com/content/13/10/e075049"doi:10.1136/bmjopen-2023-075049

4. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. https://pubmed.ncbi.nlm.nih.gov/33174475/"doi:10.1177/1352458520970841

MAPSS # 2025-14068

 

 

Products
Support
Company Newsletter
Beckman Coulter Life Sciences
Stay Connected
Products
Support
Company
Newsletter
Beckman Coulter Life Sciences
Stay Connected

Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

 

© 2025 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners. Some products may not be available in your country or region. Please contact your Beckman Coulter sales representative or distributor for more information.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.